Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Kenneth Headen

Psychiatry Greensboro, NC Medical Doctor

NPI 1366654329 CMS profile 288629

806 Summit Ave, Greensboro, NC 27405

Open in the dashboard

General payments

$9,473

382 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Kenneth Headen of Greensboro, NC is reported in the CMS Open Payments database as having received $9,473 across 382 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $295 10
2022 General $223 12
2021 General $809 42
2020 General $3,481 143
2019 General $4,664 175

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kenneth Headen
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Kenneth Headen were reported at $0. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Kenneth Headen Psychiatry median Middle half National median
2019 $4,664 $184 $59–$605 $163
2020 $3,481 $119 $36–$372 $114
2021 $809 $143 $43–$576 $132
2022 $223 $153 $50–$590 $149
2023 $295 $170 $56–$651 $160
2024 $0 $179 $57–$673 $164
2025 $0 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Allergan Inc. $3,292 67 payments
  2. Otsuka America Pharmaceutical, Inc. $949 43 payments
  3. Sunovion Pharmaceuticals Inc. $944 64 payments
  4. Janssen Pharmaceuticals, Inc $710 26 payments
  5. Neurocrine Biosciences, Inc. $651 28 payments
  6. Lundbeck LLC $510 34 payments
  7. Teva Pharmaceuticals USA, Inc. $495 28 payments
  8. Validus Pharmaceuticals LLC $466 12 payments
  9. Alkermes, Inc. $457 24 payments
  10. Vanda Pharmaceuticals Inc. $264 17 payments
  11. Other $736 39 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $6,651 373 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,600 2 payments
  3. Education $215 5 payments
  4. Gift $6 2 payments
Products named General payments · program years 2019–2023
  1. VRAYLAR $3,292 67 payments
  2. LATUDA $944 64 payments
  3. ABILIFY MAINTENA $861 37 payments
  4. SPRAVATO $500 20 payments
  5. Equetro $466 12 payments
  6. REXULTI $444 26 payments
  7. AUSTEDO $423 27 payments
  8. INVEGA SUSTENNA $388 18 payments
  9. INGREZZA $371 19 payments
  10. INVEGA TRINZA $297 12 payments
  11. Other $3,454 170 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

382 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record